Interleukin-10 gene polymorphism influences the prognosis of T-cell non-Hodgkin lymphomas.
Interleukin-10 (IL-10) is one of the cytokines implicated in the pathogenesis of diffuse large B-cell lymphoma (DLBCL) in which it acts as auto/paracrine growth factor for lymphoma growth. T-cell non-Hodgkin lymphoma (NHL) is a heterogeneous disease, the biological basis of which is not fully understood. Some evidence suggests that IL-10 might be associated with the progression of T-cell NHLs and that IL-10 may be involved in a rescue effect, protecting T cells from apoptotic cell death associated with upregulated bcl-2 expression. The current study evaluated the impact of IL-10 gene (IL10) polymorphism on the response to chemotherapy and survival in T-cell NHL. IL10 polymorphisms were determined in 108 patients with T-cell NHL. The response to chemotherapy was not dependent on IL10 polymorphism, while survival differed significantly according to IL10 polymorphism. The group with ATA haplotype showed superior overall survival (61.2 +/- 5.9% vs. 21.2 +/- 11.7%, P = 0.001) and failure-free survival (35.0 +/- 5.7% vs. 13.2 +/- 8.7%, P = 0.001) compared to those without ATA haplotype. The ATA haplotype was identified as a favourable prognostic factor compared to non-ATA haplotype (P = 0.037, hazard ratio 2.1), together with international prognostic index (IPI) in a multivariate model for overall survival. In conclusion, IL10 polymorphism may affect the survival of T-cell NHL patients.
Lee
Je-Jung
JJ
Department of Haematology/Oncology, Chonnam National University Hwasun Hospital, Jeollanamdo, Korea.
Kim
Dong Hwan
DH
Lee
Nan Young
NY
Sohn
Sang Kyun
SK
Kim
Jong Gwang
JG
Kim
Hyeoung-Joon
HJ
Do
Young Rok
YR
Park
Yeon Hee
YH
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D006239:Haplotypes; D006801:Humans; D016753:Interleukin-10 / Q000235:genetics*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D016399:Lymphoma, T-Cell / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D015996:Survival Rate; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D016753:Interleukin-10